Literature DB >> 17072329

Current insights into the regulation of programmed cell death by NF-kappaB.

J Dutta1, Y Fan, N Gupta, G Fan, C Gélinas.   

Abstract

The nuclear factor-kappaB (NF-kappaB) transcription factors have emerged as major regulators of programmed cell death (PCD) whether via apoptosis or necrosis. In this context, NF-kappaB's activity has important ramifications for normal tissue development, homoeostasis and the physiological functions of various cell systems including the immune, hepatic, epidermal and nervous systems. However, improper regulation of PCD by NF-kappaB can have severe pathologic consequences, ranging from neurodegeneration to cancer, where its activity often precludes effective therapy. Although NF-kappaB generally protects cells by inducing the expression genes encoding antiapoptotic and antioxidizing proteins, its role in apoptosis and necrosis can vary markedly in different cell contexts, and NF-kappaB can sensitize cells to death-inducing stimuli in some instances. This article describes our current knowledge of the role of NF-kappaB in apoptosis and necrosis, and focuses on the many advances since we last reviewed this rapidly evolving topic in Oncogene 3 years ago. There has been substantial progress in understanding NF-kappaB's mode of action in apoptosis and necrosis and the mechanisms that regulate its anti- vs proapoptotic activities. These recent developments shed new light on the role of NF-kappaB in many disease conditions including tumor development, tumor progression and anticancer treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17072329     DOI: 10.1038/sj.onc.1209938

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  154 in total

1.  Salicylate-induced degeneration of cochlea spiral ganglion neurons-apoptosis signaling.

Authors:  L Wei; D Ding; R Salvi
Journal:  Neuroscience       Date:  2010-03-15       Impact factor: 3.590

2.  RNAi screening identifies TAK1 as a potential target for the enhanced efficacy of topoisomerase inhibitors.

Authors:  S E Martin; Z-H Wu; K Gehlhaus; T L Jones; Y-W Zhang; R Guha; S Miyamoto; Y Pommier; N J Caplen
Journal:  Curr Cancer Drug Targets       Date:  2011-10       Impact factor: 3.428

Review 3.  Cyclooxygenases and lipoxygenases in cancer.

Authors:  Claus Schneider; Ambra Pozzi
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

4.  NF-kappaB signaling in the aging process.

Authors:  Antero Salminen; Kai Kaarniranta
Journal:  J Clin Immunol       Date:  2009-05-01       Impact factor: 8.317

5.  Nuclear factor-kappaB binds to the Epstein-Barr Virus LMP1 promoter and upregulates its expression.

Authors:  Pegah Johansson; Ann Jansson; Ulla Rüetschi; Lars Rymo
Journal:  J Virol       Date:  2008-11-19       Impact factor: 5.103

6.  Legionella pneumophila EnhC is required for efficient replication in tumour necrosis factor alpha-stimulated macrophages.

Authors:  Mingyu Liu; Gloria M Conover; Ralph R Isberg
Journal:  Cell Microbiol       Date:  2008-06-28       Impact factor: 3.715

Review 7.  NF-κB control of T cell development.

Authors:  Steve Gerondakis; Thomas S Fulford; Nicole L Messina; Raelene J Grumont
Journal:  Nat Immunol       Date:  2014-01       Impact factor: 25.606

8.  Toxoplasma GRA15 limits parasite growth in IFNγ-activated fibroblasts through TRAF ubiquitin ligases.

Authors:  Debanjan Mukhopadhyay; Lamba Omar Sangaré; Laurence Braun; Mohamed-Ali Hakimi; Jeroen Pj Saeij
Journal:  EMBO J       Date:  2020-04-15       Impact factor: 11.598

Review 9.  Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities.

Authors:  Jessica Plati; Octavian Bucur; Roya Khosravi-Far
Journal:  J Cell Biochem       Date:  2008-07-01       Impact factor: 4.429

10.  PUMA is directly activated by NF-kappaB and contributes to TNF-alpha-induced apoptosis.

Authors:  P Wang; W Qiu; C Dudgeon; H Liu; C Huang; G P Zambetti; J Yu; L Zhang
Journal:  Cell Death Differ       Date:  2009-05-15       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.